Back to search

National and Kapodistrian University of Athens

Ανάπτυξη μεθόδων μέτρησης των υποδοχέων οιστρογόνων ERβ1 και ERβ2 και αξιολόγηση τους ως δεικτών πρόγνωσης του καρκίνου του μαστού

Abstract

dc:description

Estrogen action is primarily mediated by the two subtypes of estrogen receptor (ER), ERα and ERβ. There are at least five ERβ isoforms in humans, of which two, namely ERβ1 and ERβ2, are primarily expressed in breast tissue, with ERβ1 being the only isoform that is able to bind hormone with high affinity. While ERα is established since long ago as a marker of favorable breast cancer prognosis and response to hormone therapy, the clinical significance of ERβ1 and ERβ2 is not clear as yet. In addition, little is known about the role of ERβ1 and ERβ2 in benign hyperplastic lesions of the breast and, in particular, the breast cancer risk of these lesions. To study the role of ERβ1 and ERβ2 in breast cancer and benign breast lesions, we characterized a series of new monoclonal and polyclonal antibodies using cells transiently or stably trasnfected with ERα, ERβ1 or ERβ2, including e.g. clones of human embryonic kidney cells HEK-293 engineered to stably express ERα and ERβ1. Using antibodies characterized as most suitable for immunohistochemistry, we found that, compared to ERα and ΕRβ2, ERβ1 is more frequently expressed in hyperplastic (HUT) and non-invasive neoplastic lesions (ADH, DCIS) of human breast. We also found that, while the percentage of ERα-expressing cells increases progressively from HUT to ADH and DCIS, that of ERβ2-expressing cells decreases from normal breast to ADH. In addition, we found that expression of Ki-67 was associated with ERα positivity in HUT and inversely associated with ERβ2 positivity in DCIS. These findings are taken to indicate that ERβ2 expression is dynamically regulated during mammary carcinogenesis and that ERβ2 could have a protective role with respect to DCIS progression. In ERα-negative breast cancer, ERβ1(+) was detected in 66 out of 97 (68%) cases and ERβ2(+) in 65 out of 96 (68%) cases. Tumour grade was significantly higher in ERβ1-negative cases compared to positive cases, while ERβ2 expression was positively correlated with lymph node metastasis. We did not find any relation between ERβ1 expression and patient overall or disease free survival. In contrast, ERβ2 has emerged as the most important prognostic variable after tumour grade. Patients with ERα-negative breast carcinomas that overexpress ERβ2 had lower disease free survival, independent of the type of post-operative treatment.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Chantzi, Niki
  • Χαντζή, Νίκη

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/25328

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Chantzi, Niki; Χαντζή, Νίκη. Ανάπτυξη μεθόδων μέτρησης των υποδοχέων οιστρογόνων ERβ1 και ERβ2 και αξιολόγηση τους ως δεικτών πρόγνωσης του καρκίνου του μαστού. National and Kapodistrian University of Athens, 2011. http://hdl.handle.net/10442/hedi/25328